&lt;p&gt;Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications&lt;/p&gt;

Jourdain, Gonzague; Ngo‐Giang‐Huong, Nicole; Khamduang, Woottichai

doi:10.2147/idr.s171695

Cited by 6 publications

(4 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might be due to inadequate treatment for HBsAg carrier mothers and inadequate vaccination coverage for pregnant mothers. Therefore, preventing MTCT is essential to achieving the WHO goal of HBV elimination by 2030 [ 31 ]. This can be achieved through the antiviral treatment of HBeAg-positive pregnant women and birth dose vaccination for newborns from HBsAg carrier mothers [ 18 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of Hepatitis B Virus Infection, Mother-To-Child Transmission, and Associated Risk Factors Among Delivering Mothers in Tigray Region, Northern Ethiopia: a Cross-Sectional Study

et al. 2020

View full text Add to dashboard Cite

Introduction High prevalence of hepatitis B virus (HBV) infection among pregnant women is the primary source of infection for their children and the general population. Mother-to-child transmission (MTCT) is the primary mode of transmission in endemic areas like Ethiopia. The aim of this study was to determine the prevalence of HBV infection, rate of MTCT, and associated risk factors among delivering mothers. Methods This health facility-based cross-sectional study was conducted in four public hospitals of the Eastern zone of Tigray among 473 delivering mothers. Structured questionnaires and laboratory results were used to collect the data. The data were checked for completeness and entered into EpiData manager version 4.6.0.0. Then the data were exported to Statistical Package for Social Sciences (SPSS) version 23. The odds ratio, along with a 95% confidence interval, was estimated to identify predictors of HBV infection using multivariable logistic regression analysis. Significant association was considered at p < 0.05. Results A total of 473 mothers were enrolled, and the response rate was 100%. The prevalence of HBV infection among the mothers and the rate of MTCT of the infection were 11.6% and 30.9%, respectively. History of home delivery [adjusted odds ratio (AOR) = 4.5, 95% confidence interval (CI) (2, 10.6)], history of hospital admission [AOR = 5, 95% CI (2.2, 11.5)], working at health facility [AOR = 5.4, 95% CI (1.4, 20.7)], body tattoos [AOR = 5.8, 95% CI (2.4, 13.6)], sharing personal care materials [AOR = 3.8, 95% CI (1.4, 9.9)], insufficient knowledge [AOR = 5.6, 95% CI (1.6, 19)], and having human immunodeficiency virus (HIV) [AOR = 5.1, 95% CI (1, 26.2)] were significantly associated with HBV infection. Conclusion HBV infection among delivering women is becoming highly endemic, and the rate of MTCT was high. Therefore, administering hepatitis B vaccine to all neonates within 24 h of birth is mandatory to prevent MTCT of HBV infection and related complications. Furthermore, health education and dissemination of information about HBV for the pregnant mothers are needed to reduce HBV infection and vertical transmission in Ethiopia.

show abstract

Section: Discussionmentioning

confidence: 99%

Seroprevalence of Hepatitis B Virus Infection, Mother-To-Child Transmission, and Associated Risk Factors Among Delivering Mothers in Tigray Region, Northern Ethiopia: a Cross-Sectional Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The results demonstrated that abnormal ALT levels after delivery was not associated with LAM or LdT treatment during pregnancy and postpartum treatment cessation. Previous studies showed that increased production of adrenal corticosteroids, estrogen, and progesterone and increased amounts of regulatory T cells were related to maternal immune suppression, which prevents rejection of the fetus during pregnancy [22,23]. Recovery in the immune system from suppression to activation after delivery resulted in hepatitis B flares [24].…”

Section: Biomed Research Internationalmentioning

confidence: 99%

Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother‐to‐Child Transmission of Hepatitis B Virus: A Real‐World Study

Duan

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. There are few large sample studies evaluating the safety and efficacy of lamivudine (LAM) or telbivudine (LdT) in preventing hepatitis B mother-to-child transmission (MTCT) in highly viremic mothers in the third trimester of pregnancy in real-world settings. The purpose of this study was to analyze a large sample size of HBV-infected mothers to better understand the safety and efficacy of LAM and LdT under the aforementioned criteria. Methods. During the period of November 2008 to November 2017, we retrospectively enrolled mothers with HBV DNA>1×106 IU/mL who received LAM or LdT during the third trimester of pregnancy and compared them to untreated mothers. All mothers were divided into the three following groups: the LAM group, the LdT group, and the control group. Results. A total of 2624 HBV-infected mothers were enrolled in the study, with 363 in the LAM group, 1283 in the LdT group, and 978 in the control group. The MTCT rates were significantly lower in the LAM or LdT group than that in the control group (0.4% or 0.3% versus 9.0%, P<0.001). Infants born to untreated mothers had a significantly higher risk of HBV infection (OR=28.6, 95% CI: 10.4–78.7, P<0.001). There were no significant differences in perinatal complications between the three groups (P>0.05). There were also no differences for gestational age or infants’ height, weight, Apgar scores, or birth defect rates. Postpartum discontinuation of antiviral therapy did not seem to increase the risk of postpartum alanine aminotransferase (ALT) flare. Conclusion. LAM or LdT treatment initiated in the third trimester for mothers with HBV DNA>1×106 IU/mL was equally safe and effective in preventing MTCT.

show abstract

“…Major themes, barriers, and solutions are outlined in Table 2. [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]…”

Section: Resultsmentioning

confidence: 99%

Implementation Approaches for Introducing and Overcoming Barriers to Hepatitis B Birth-Dose Vaccine in sub-Saharan Africa

Boisson

Goel

Yotebieng

et al. 2022

Glob Health Sci Pract

View full text Add to dashboard Cite

A review of 39 articles outlining the experience of introducing the hepatitis B birth-dose (HepB-BD) vaccine in low-and middle-income countries in sub-Saharan Africa identifies the potential barriers to the vaccine's uptake.n Empirical examples of policy makers targeting the mother's role to increase uptake of HepB-BD vaccine at the community level are strikingly scarce, and efforts to leverage community-level resources and reach remote areas have been limited.

show abstract

<p>Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications</p>

Cited by 6 publications

References 87 publications

Seroprevalence of Hepatitis B Virus Infection, Mother-To-Child Transmission, and Associated Risk Factors Among Delivering Mothers in Tigray Region, Northern Ethiopia: a Cross-Sectional Study

Seroprevalence of Hepatitis B Virus Infection, Mother-To-Child Transmission, and Associated Risk Factors Among Delivering Mothers in Tigray Region, Northern Ethiopia: a Cross-Sectional Study

Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother‐to‐Child Transmission of Hepatitis B Virus: A Real‐World Study

Implementation Approaches for Introducing and Overcoming Barriers to Hepatitis B Birth-Dose Vaccine in sub-Saharan Africa

Contact Info

Product

Resources

About